



February 04, 2020

The General Manager
Department of Corporate Services CRD,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Dear Sir

Subject: **Outcome of Board Meeting.**

This has reference to our letter dated 23rd January, 2020.


- 1) Un-audited (Standalone & Consolidated) financial results of the company for the quarter ended 31st December, 2019 (copy enclosed).
- 2) Copies of the Limited Review Reports as submitted by the Statutory Auditors of the company on (Standalone & Consolidated) financial results for the quarter ended 31st December, 2019 (copy enclosed).
- 3) The board has discussed and passed unanimously appropriate resolution to restructure the promoters holding.
- 4) The board has discussed and passed appropriate resolution on the order passed by SEBI in the matter of recovery of lost GDR funds.


This is for your kind information and records.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

VIKRAM POLAVRAPU
MANAGING DIRECTOR





TRANSGENE BIOTEK LIMITED

68, 69 & 70, Anrich Industrial Area, Bollaram, Medak District - 503325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2019

(Amount in Rs.)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---------|--|---------------------------|---------------------------|-------------------------|-------------------------|
| | | 31.12.2019 (Unaudited) | 30.09.2019 (Unaudited) | 31.12.2018 (Audited) | 31.03.2019 (Audited) |
| 1 | Revenue from operations | - | - | - | 7,12,870 |
| 2 | Other income (net) | 4,38,470 | 5,09,164 | 4,38,470 | 2,03,77,778 |
| 3 | Total income (1 + 2) | 4,38,470 | 5,09,164 | 4,38,470 | 2,10,90,648 |
| 4 | EXPENSES | | | | |
| | Cost of materials consumed | 55,732 | 6,590 | 1,24,956 | 3,38,525 |
| | Purchase of Stock-in-trade | - | - | - | - |
| | Changes in inventories of finished goods, work-in-progress and Stock-in-trade | - | - | - | - |
| | Employee benefits expense | 7,14,017 | 7,07,850 | 5,94,507 | 24,81,867 |
| | Finance costs | 7,51,534 | 7,51,534 | 6,26,374 | 25,05,496 |
| | Depreciation and amortisation expense | 2,47,42,286 | 2,47,42,286 | 2,47,30,333 | 9,89,42,929 |
| | Other expenses | 7,87,947 | 16,27,207 | 13,57,954 | 47,48,967 |
| | Total expenses | 2,70,51,516 | 2,78,35,467 | 2,74,34,124 | 10,90,17,784 |
| 5 | Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4) | (2,66,13,046) | (2,73,26,303) | (2,69,95,654) | (8,79,27,136) |
| 6 | Exceptional item (net) | - | - | - | - |
| 7 | Profit/(Loss) on sale of property, plant & equipment | - | - | 1,77,38,173 | - |
| | Profit before tax (5 - 6) | (2,66,13,046) | (2,73,26,303) | (92,57,481) | (8,79,27,136) |
| 8 | Tax expense | | | | |
| | Tax adjustments for earlier years | - | - | - | - |
| | Current tax | - | - | - | - |
| | Deferred tax | - | - | - | - |
| | Total tax expense | - | - | - | - |
| 9 | Profit for the year (7 - 8) | (2,66,13,046) | (2,73,26,303) | (92,57,481) | (8,79,27,136) |
| 10 | Other comprehensive income | | | | |
| | A Items that will not be reclassified subsequently to profit or loss | - | - | 300 | (5,005) |
| | (a) Remeasurements cost of post employment benefits | - | - | 300 | (5,005) |
| | Total other comprehensive income | - | - | 300 | (5,005) |
| 11 | Total comprehensive income for the year (9 + 10) | (2,66,13,046) | (2,73,26,303) | (92,57,181) | (8,79,32,141) |
| 12 | Earnings per equity share | | | | |
| | (Equity shares, par value of Rs. 10 each) | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 |
| | Basic (Rs.) | (0.35) | (0.36) | (0.12) | (1.16) |
| | Diluted (Rs.) | (0.35) | (0.36) | (0.12) | (1.16) |

For TRANSGENE BIOTEK LIMITED

Managing Director

Date: 04/02/2020
Place: Hyderabad



NOTES TO THE ACCOUNTS – Q3 2019-20

- 1) With festive season across north America and Europe, we received intimation from potential partners' about the delay in initiating studies using our TrabiORAL technology to deliver their chosen molecules orally.
- 2) Our appeal at SAT is scheduled to be heard on 11th February 2020.
- 3) SEBI Adjudication hearing is on 5th February 2020.
- 4) No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
- 5) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 04th Feb 2020.

TRANSGENE BIOTEK LTD.

Managing Director

TRANSGENE BIOTEK LIMITED


Notes forming part of the Standalone financial statements


Other operating expenses

| Particulars | For the Period ended December 31, 2019 |
|---------------------------------|---|
| Travelling and conveyance | 1,000 |
| Telephone exp | 8,697 |
| Freight Exp | 1,663 |
| Director Sitting Fees | 10,000 |
| Bank charges | 90 |
| Power and fuel | 2,39,874 |
| Repairs and Maintenance | 3,930 |
| Printing & Stationary | 400 |
| Legal & professional charges | 3,34,693 |
| Patents application filing fees | 44,257 |
| Postage and courier | 84,541 |
| Insurance | 28,418 |
| Office maintainence | 4,790 |
| Miscellaneous expenses | 25,594 |
| Total | 7,87,947 |

for TRANSGENE BIOTEK LTD.

Managing Director



**TRANSGENE BIOTEK LIMITED**

68, 69 & 70, Anrich Industrial Area, Bollaram, Medak District - 503325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2019

(Amount in Rs.)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|--|---------------------------|---------------------------|-------------------------|-------------------------|----------------------|
| | | 31.12.2019 (Unaudited) | 30.09.2019 (Unaudited) | 31.12.2018 (Audited) | 31.03.2019 (Audited) | |
| 1 | Revenue from operations | - | - | - | - | 7,12,870 |
| 2 | Other income (net) | 4,38,470 | 5,09,164 | 4,38,470 | 4,38,470 | 2,03,77,778 |
| 3 | Total income (1 + 2) | 4,38,470 | 5,09,164 | 4,38,470 | 4,38,470 | 2,10,90,648 |
| 4 | EXPENSES | | | | | |
| | Cost of materials consumed | 55,732 | 6,590 | 1,24,956 | 1,24,956 | 3,38,525 |
| | Purchase of Stock-in-trade | - | - | - | - | - |
| | Changes in inventories of finished goods, work-in-progress and Stock-in-trade | - | - | - | - | - |
| | Employee benefits expense | 7,14,017 | 7,07,850 | 5,94,507 | 5,94,507 | 24,81,867 |
| | Finance costs | 7,51,534 | 7,51,534 | 6,26,374 | 6,26,374 | 25,05,496 |
| | Depreciation and amortisation expense | 2,47,42,286 | 2,47,42,286 | 2,47,30,333 | 2,47,30,333 | 9,89,42,929 |
| | Other expenses | 7,87,947 | 16,27,207 | 13,57,954 | 13,57,954 | 47,48,967 |
| | Total expenses | 2,70,51,516 | 2,78,35,467 | 2,74,34,124 | 2,74,34,124 | 10,90,17,784 |
| 5 | Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4) | (2,66,13,046) | (2,73,26,303) | (2,69,95,654) | (2,69,95,654) | (8,79,27,136) |
| 6 | Exceptional item (net) | - | - | - | - | - |
| 7 | Profit/(Loss) on sale of property, plant & equipment | - | - | 1,77,38,173 | 1,77,38,173 | - |
| 8 | Profit before tax (5 - 6) | (2,66,13,046) | (2,73,26,303) | (92,57,481) | (92,57,481) | (8,79,27,136) |
| | Tax expense | | | | | |
| | Tax adjustments for earlier years | - | - | - | - | - |
| | Current tax | - | - | - | - | - |
| | Deferred tax | - | - | - | - | - |
| | Total tax expense | - | - | - | - | - |
| 9 | Profit for the year (7 - 8) | (2,66,13,046) | (2,73,26,303) | (92,57,481) | (92,57,481) | (8,79,27,136) |
| 10 | Other comprehensive income | | | | | |
| | A Items that will not be reclassified subsequently to profit or loss | - | - | - | - | - |
| | (a) Remeasurements cost of post employment benefits | - | - | 300 | 300 | (5,005) |
| | Total other comprehensive income | - | - | 300 | 300 | (5,005) |
| 11 | Total comprehensive income for the year (9 + 10) | (2,66,13,046) | (2,73,26,303) | (92,57,181) | (92,57,181) | (8,79,32,141) |
| 12 | Earnings per equity share | | | | | |
| | (Equity shares, par value of Rs. 10 each) | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 |
| | Basic (Rs.) | (0.35) | (0.36) | (0.12) | (0.12) | (1.16) |
| | Diluted (Rs.) | (0.35) | (0.36) | (0.12) | (0.12) | (1.16) |

For TRANSGENE BIOTEK LIMITED




Managing Director

Date: 04/02/2020
Place: Hyderabad

NOTES TO THE ACCOUNTS – Q3 2019-20

- 1) With festive season across north America and Europe, we received intimation from potential partners' about the delay in initiating studies using our TrabiORAL technology to deliver their chosen molecules orally.
- 2) Our appeal at SAT is scheduled to be heard on 11th February 2020.
- 3) SEBI Adjudication hearing is on 5th February 2020.
- 4) No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.
- 5) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 04th Feb 2020.

TRANSGENE BIOTEK LTD.



Managing Director


TRANSGENE BIOTEK LIMITED

Notes forming part of the Consolidated financial statements

Other operating expenses

| Particulars | For the Period ended December 31, 2019 |
|---------------------------------|---|
| Travelling and conveyance | 1,000 |
| Telephone exp | 8,697 |
| Freight Exp | 1,663 |
| Director Sitting Fees | 10,000 |
| Bank charges | 90 |
| Power and fuel | 2,39,874 |
| Repairs and Maintenance | 3,930 |
| Printing & Stationary | 400 |
| Legal & professional charges | 3,34,693 |
| Patents application filing fees | 44,257 |
| Postage and courier | 84,541 |
| Insurance | 28,418 |
| Office maintainence | 4,790 |
| Miscellaneous expenses | 25,594 |
| Total | 7,87,947 |

or TRANSGENE BIOTEK LTD.


Managing Director



Limited Review Report

To,

The Board of directors

M/s. Transgene Biotek Limited


Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 31 December 2019 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. Our view of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities

| Name of the entity | Relationship |
|--------------------------------|---------------------|
| 1. Transgene Biotek HK Limited | Subsidiary |

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of one subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 31 December 2019, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S


Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date: 27/01/2020




Unique Document Identification Number (UDIN) for this document is
20212664AAAAAB2725

Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Tansgene Biotek Limited for the quarter ended 31 December 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S


Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date:27/01/2020

